ES
MARKETS / NYSE / MMM
NYSE · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · LARGE CAP

3M Company MMM

19 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$24.9B
▲ 1.5% vs FY2024
EPS · FY25
$6.00
Dividend / sh · FY25
$2.92
Payout · FY25
48%
ROE · FY25
76.1%
Net margin · FY25
13.0%
Dividend coverage
2.1×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 24.9B
Revenue, FY2025 · full 19-year series below
Revenue Net income
1020304024.93.22007201020132016201920222025
1020304024.93.22016201920222025

13 cents of every revenue dollar became profit this year.

Per share
USD 6.00
Diluted EPS, FY2025
EPS Dividend
48122.926.002007201020132016201920222025
48122.926.002016201920222025

Earnings covered the dividend 2.1 times — the rest stayed in the company.

Profitability
76.1%
Return on equity, FY2025
ROE
25507510076.1%2007201020132016201920222025
25507510076.1%2016201920222025
Operating margin18.6%
Net margin13.0%
Return on assets8.4%

Each USD of equity produced 76 cents of profit this year.

Returned to shareholders
USD 4.8B
returned in FY2025 · dividends + net buybacks
Dividends paidUSD 1.6B
Net buybacksUSD 3.3B
Share of profit148.1%
Consecutive raises—

USD 1.6B in dividends and USD 3.3B in buybacks — 148% of the year's profit, so the payout drew on cash built up earlier.

Growth
−5.0% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−1.6%
−5.0%
−1.9%
−0.4%
Net income
−17.4%
−9.8%
−3.9%
−1.5%
EPS, diluted
−16.2%
−8.5%
−2.3%
+0.4%
Dividend / share
−21.2%
−13.1%
−0.5%
+2.2%
Returned to shareholders
−0.1%
+5.1%
−4.7%
+4.9%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.53B
Shares outstanding, FY2025
0.690.532007201020132016201920222025
0.600.532016201920222025
Change, 5 years−8.2%
Change, 10 years−13.0%

The share count shrank 8% in five years — the same company, cut into fewer, larger slices.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 37.7B
total assets, end of FY2025
Total assetsUSD 37.7B
EquityUSD 4.7B
CashUSD 5.2B
Gross debtUSD 12.6B
Net debtUSD 7.4B
Current ratio1.71×

Net debt stands at 157% of equity.

History
19 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Revenue $B
24.9
24.6
24.6
26.2
35.4
32.2
32.1
32.8
31.7
30.1
30.3
31.8
30.9
29.9
29.6
26.7
23.1
25.3
24.5
Operating income $B
4.6
4.8
−10.7
4.4
7.4
7.2
6.2
7.2
7.7
7.0
6.9
7.1
6.7
6.5
6.2
5.9
4.8
5.2
6.2
EBITDA $B
5.9
6.2
−8.7
6.2
9.3
9.1
7.8
8.7
9.2
8.5
8.4
8.5
8.0
7.8
7.4
7.0
6.0
6.4
·
Income tax $B
1.0
0.8
−2.9
0.2
1.3
1.3
1.1
1.6
2.7
2.0
2.0
2.0
1.8
1.8
1.7
1.6
1.4
1.6
2.0
Net income $B
3.2
4.2
−7.0
5.8
5.9
5.4
4.5
5.3
4.9
5.0
4.8
5.0
4.7
4.4
4.3
4.1
3.2
3.5
4.1
EPS, diluted $
6.00
7.55
−12.63
10.18
10.12
9.36
7.72
8.89
7.93
8.16
7.58
7.49
6.72
6.32
5.96
5.63
4.52
4.89
5.60
Dividend / sh $
2.92
3.61
6.00
5.96
5.92
5.88
5.76
5.44
4.70
4.44
3.08
3.59
3.40
2.36
2.20
2.10
2.04
2.00
1.92
Payout %
48
47
−47
58
58
62
73
60
58
53
53
45
37
37
36
37
44
40
34
ROE %
76.1
96.5
−71.6
38.8
42.4
47.5
45.5
50.1
44.4
46.5
39.4
32.4
26.6
26.9
27.6
28.7
28.7
35.0
·
Shares out B
0.53
0.54
0.55
0.55
0.57
0.58
0.58
0.58
0.59
0.60
0.61
0.64
0.66
0.69
0.69
0.71
0.71
0.69
·

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
55 of 55
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed